People: Targacept Inc (TRGT.O)
4.89USD
18 Jun 2013
$0.08 (+1.66%)
$4.81
$4.83
$4.92
$4.74
92,164
175,437
$5.77
$3.85
Bencherif, Merouane
Brief Biography
Mr. Merouane Bencherif, M.D., Ph.D., serves as Senior Vice President - Preclinical Research of Targeacept Inc. He was Company's Vice President, Preclinical Research from August 2002 to March 2010 and Company's Vice President, Biological Sciences from August 2000 to August 2002.
Basic Compensation
| Total Annual Compensation, USD | Long-Term Incentive Plans, USD | All Other, USD | Fiscal Year Total, USD |
|---|---|---|---|
| 271,471 | -- | 167,173 | 438,644 |
Options Compensation
| Quantity | Market Value | |
|---|---|---|
| Excercisable | 102,772 | -- |
| Unexercisable | 52,470 | -- |
| Excercised | -- | -- |
| Name | Fiscal Year Total |
|---|---|
Mark Skaletsky |
-- |
Stephen Hill |
-- |
Alan Musso |
1,145,620 |
Peter Zorn |
1,120,620 |
Merouane Bencherif |
438,644 |
Mauri Hodges |
-- |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
